Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
Keytruda Runner-Up for Science Breakthrough of the Year
The Lustgarten Foundation shares the story that Keytruda (pembrolizumab) is a runner-up in Science magazine’s Breakthrough of the year.
Chemotherapy, Immunotherapy, and Radiation for Locally Advanced Pancreatic Cancer
A clinical trial is testing chemotherapy that enhances the action of two immunotherapy drugs and SBRT to stop locally advanced pancreatic cancer.
Presurgical Treatment for Pancreatic Cancer That Is Removable
A clinical trial looks at immunotherapy plus vitamin D plus standard chemotherapy before surgery to remove pancreatic cancer.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
Immunotherapy to Help Shrink Pancreatic Tumors for Surgery
Researchers are looking at adding checkpoint drugs–a type of immunotherapy–to standard chemoradiation to shrink pancreatic cancer for surgery.